Name: DUPIXENT@(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Sandri Johnson, NP
Start: 2025-11-12T12:15:00-05:00
End: 2025-11-12T13:15:00-05:00
Location: Virtual (Zoom)

Oct 2025
- Wed 29
  - 12:15 pm - 1:15 pm PDT
    
    Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
    by Ben Ehst, MD
- Thu 30
  - 12:15 pm - 1:15 pm EDT
    
    A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
    by Marc Serota, MD
Nov 2025
- Mon 3
  - 12:15 pm - 12:45 pm EST
    
    A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
    by Karan Lal, DO
  - 12:15 pm - 1:15 pm CST
    
    DUPIXENT^@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
    by Omar Noor, MD
- Tue 4
  - 12:15 pm - 1:15 pm MST
    
    Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
    by Autumn Burnette, MD
- Thu 6
  - 12:15 pm - 1:15 pm EST
    
    Clinical Case Discussion: An Adolescent Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
    by Amy Spizuoco, DO
  - 12:15 pm - 1:15 pm MST
    
    Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
    by Daniel Butler, MD
- Mon 10
  - 12:15 pm - 1:15 pm EST
    
    Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
    by Leigh Ann Pansch, NP
  - 12:15 pm - 1:15 pm PST
    
    DUPIXENT^@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
    by Lakshi Aldredge, NP
- Wed 12
  - 12:15 pm - 1:15 pm EST
    
    DUPIXENT^@(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
    by Sandri Johnson, NP

Oct 2025

Wed 29

Thu 30

Nov 2025

Mon 3

Tue 4

Thu 6

Mon 10

Wed 12